Review



antagonist fk888  (Tocris)


Bioz Verified Symbol Tocris is a verified supplier
Bioz Manufacturer Symbol Tocris manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 91
      Buy from Supplier

    Structured Review

    Tocris antagonist fk888
    (A) Protocol for treatment of WT mice with either 3 i.n. doses every other day of PBS (gray), FAM with blank peptide conjugated to saporin (FAM 3X+Blank-SP, blue), [Sar ,Met(O 2 ) ]–Substance P conjugated to saporin (SSP-SAP 3X, green), or FAM with SSP-SAP (SSP-SAP 3X + FAM 3X, red) analyzed on D5. Data depicted in (C), (E), (G), (H), (K), (L), (O), and (P). (B) Protocol for treatment of WT mice with 3 i.n. doses every other day of either the NK1R inhibitor <t>FK888</t> and PBS (FK888 3X + PBS 3X, gray), vehicle with FAM (Vehicle 3X + FAM 3X, blue), the NK1R inhibitor with Sar-SP (FK888 3X + Sar-SP 3X, green), or FK888 with FAM (FK888 3X + FAM 3X, red). Data depicted in (D), (F), (I), (J), (M), (N), (Q), and (R). (C-D) Sinonasal wash levels of IL-5 (left) and IL-13 (right) in (C) protocol (A), ablate or (D) protocol (B), inhibit. (E-F) Sinonasal wash levels of (E) IL-25 (left) and CysLT (right) for protocol (A, ablate) or (F) for protocol (B, inhibit). (G-J) Total number of respiratory tissue (G,I) Tuft-1 and (H,J) Tuft-2 cells in the (G-H) protocol (A), ablate or (I-J) in protocol (B), inhibit. (K-N) Total number of respiratory tissue (K, M) Ki-67+ basal cells and (L, M) ILC2s in (K-L) protocol (A), ablate or (M-N) protocol (B) inhibit. (O-R) Total number of respiratory tissue (O, Q) CD4+ TH2 cells and (P, R) eosinophils in (O-P) protocol (A), ablate or (Q-R) protocol (B), inhibit. Data are mean ± SEM, representative of 2 experiments (4-5 mice/treatment), one-way ANOVA with Tukey’s post-hoc tests. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001. See also and .
    Antagonist Fk888, supplied by Tocris, used in various techniques. Bioz Stars score: 91/100, based on 19 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/antagonist+fk888/FK+888/bio_rxiv__2023__07__04__547596-283-9-11
    Average 91 stars, based on 19 article reviews
    antagonist fk888 - by Bioz Stars, 2026-10
    91/100 stars

    Images

    1) Product Images from "Neuron-dependent tuft cell expansion initiates sinonasal allergic Type 2 inflammation"

    Article Title: Neuron-dependent tuft cell expansion initiates sinonasal allergic Type 2 inflammation

    Journal: bioRxiv

    doi: 10.1101/2023.07.04.547596

    (A) Protocol for treatment of WT mice with either 3 i.n. doses every other day of PBS (gray), FAM with blank peptide conjugated to saporin (FAM 3X+Blank-SP, blue), [Sar ,Met(O 2 ) ]–Substance P conjugated to saporin (SSP-SAP 3X, green), or FAM with SSP-SAP (SSP-SAP 3X + FAM 3X, red) analyzed on D5. Data depicted in (C), (E), (G), (H), (K), (L), (O), and (P). (B) Protocol for treatment of WT mice with 3 i.n. doses every other day of either the NK1R inhibitor FK888 and PBS (FK888 3X + PBS 3X, gray), vehicle with FAM (Vehicle 3X + FAM 3X, blue), the NK1R inhibitor with Sar-SP (FK888 3X + Sar-SP 3X, green), or FK888 with FAM (FK888 3X + FAM 3X, red). Data depicted in (D), (F), (I), (J), (M), (N), (Q), and (R). (C-D) Sinonasal wash levels of IL-5 (left) and IL-13 (right) in (C) protocol (A), ablate or (D) protocol (B), inhibit. (E-F) Sinonasal wash levels of (E) IL-25 (left) and CysLT (right) for protocol (A, ablate) or (F) for protocol (B, inhibit). (G-J) Total number of respiratory tissue (G,I) Tuft-1 and (H,J) Tuft-2 cells in the (G-H) protocol (A), ablate or (I-J) in protocol (B), inhibit. (K-N) Total number of respiratory tissue (K, M) Ki-67+ basal cells and (L, M) ILC2s in (K-L) protocol (A), ablate or (M-N) protocol (B) inhibit. (O-R) Total number of respiratory tissue (O, Q) CD4+ TH2 cells and (P, R) eosinophils in (O-P) protocol (A), ablate or (Q-R) protocol (B), inhibit. Data are mean ± SEM, representative of 2 experiments (4-5 mice/treatment), one-way ANOVA with Tukey’s post-hoc tests. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001. See also and .
    Figure Legend Snippet: (A) Protocol for treatment of WT mice with either 3 i.n. doses every other day of PBS (gray), FAM with blank peptide conjugated to saporin (FAM 3X+Blank-SP, blue), [Sar ,Met(O 2 ) ]–Substance P conjugated to saporin (SSP-SAP 3X, green), or FAM with SSP-SAP (SSP-SAP 3X + FAM 3X, red) analyzed on D5. Data depicted in (C), (E), (G), (H), (K), (L), (O), and (P). (B) Protocol for treatment of WT mice with 3 i.n. doses every other day of either the NK1R inhibitor FK888 and PBS (FK888 3X + PBS 3X, gray), vehicle with FAM (Vehicle 3X + FAM 3X, blue), the NK1R inhibitor with Sar-SP (FK888 3X + Sar-SP 3X, green), or FK888 with FAM (FK888 3X + FAM 3X, red). Data depicted in (D), (F), (I), (J), (M), (N), (Q), and (R). (C-D) Sinonasal wash levels of IL-5 (left) and IL-13 (right) in (C) protocol (A), ablate or (D) protocol (B), inhibit. (E-F) Sinonasal wash levels of (E) IL-25 (left) and CysLT (right) for protocol (A, ablate) or (F) for protocol (B, inhibit). (G-J) Total number of respiratory tissue (G,I) Tuft-1 and (H,J) Tuft-2 cells in the (G-H) protocol (A), ablate or (I-J) in protocol (B), inhibit. (K-N) Total number of respiratory tissue (K, M) Ki-67+ basal cells and (L, M) ILC2s in (K-L) protocol (A), ablate or (M-N) protocol (B) inhibit. (O-R) Total number of respiratory tissue (O, Q) CD4+ TH2 cells and (P, R) eosinophils in (O-P) protocol (A), ablate or (Q-R) protocol (B), inhibit. Data are mean ± SEM, representative of 2 experiments (4-5 mice/treatment), one-way ANOVA with Tukey’s post-hoc tests. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001. See also and .

    Techniques Used:

    (A-K) Outcomes in ablation experiment following PBS (gray), FAM 3X + Blank-SAP (blue), SSP-SAP 3X (green), or SSP-SAP 3X + FAM 3X (red) for: (A) sneezing-like behavior evoked by capsaicin (12µM i.n.), which was counted from 10 min sound and video recording in a treatment-blind manner, numbers and/or percentages of all (B) Tuft-1 cells, (C) NK1R+ Tuft-1 cells, (D) all Tuft-2 cells, (E) NK1R+ Tuft-2 cells, (F) total basal cells, (G) Ki67+ basal cells, (H) NK1R+ basal cells, (I) ILC2, (J) CD4+ TH2 cells, and (K) eosinophils in the respiratory epithelium assessed by flow cytometry. (L-V) Outcomes of inhibitor experiment following PBS (gray), vehicle + FAM 3X (blue), FK888 3X +SAR-SP 3X (green), or FK888 3X + FAM 3X (red) for: (L) sneezing-like behavior evoked by capsaicin, numbers and/or percentages of all (M) Tuft-1 cells, (N) NK1R+ Tuft-1 cells, (O) all Tuft-2 cells, (P) NK1R+ Tuft-2 cells, (Q) total basal cells, (R) Ki67+ basal cells, (S) NK1R+ basal cells, (T) ILC2, (U) CD4+ TH2 cells, and (V) eosinophils in the respiratory epithelium assessed by flow cytometry. Data are mean ± SEM, representative of 2 experiments (4-8 mice/treatment) one-way ANOVA with Tukey’s post-hoc tests. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001.
    Figure Legend Snippet: (A-K) Outcomes in ablation experiment following PBS (gray), FAM 3X + Blank-SAP (blue), SSP-SAP 3X (green), or SSP-SAP 3X + FAM 3X (red) for: (A) sneezing-like behavior evoked by capsaicin (12µM i.n.), which was counted from 10 min sound and video recording in a treatment-blind manner, numbers and/or percentages of all (B) Tuft-1 cells, (C) NK1R+ Tuft-1 cells, (D) all Tuft-2 cells, (E) NK1R+ Tuft-2 cells, (F) total basal cells, (G) Ki67+ basal cells, (H) NK1R+ basal cells, (I) ILC2, (J) CD4+ TH2 cells, and (K) eosinophils in the respiratory epithelium assessed by flow cytometry. (L-V) Outcomes of inhibitor experiment following PBS (gray), vehicle + FAM 3X (blue), FK888 3X +SAR-SP 3X (green), or FK888 3X + FAM 3X (red) for: (L) sneezing-like behavior evoked by capsaicin, numbers and/or percentages of all (M) Tuft-1 cells, (N) NK1R+ Tuft-1 cells, (O) all Tuft-2 cells, (P) NK1R+ Tuft-2 cells, (Q) total basal cells, (R) Ki67+ basal cells, (S) NK1R+ basal cells, (T) ILC2, (U) CD4+ TH2 cells, and (V) eosinophils in the respiratory epithelium assessed by flow cytometry. Data are mean ± SEM, representative of 2 experiments (4-8 mice/treatment) one-way ANOVA with Tukey’s post-hoc tests. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001.

    Techniques Used: Flow Cytometry

    Related Articles

    Flow Cytometry:

    Article Title: Neuron-dependent tuft cell expansion initiates sinonasal allergic Type 2 inflammation
    Article Snippet: Mice were treated 3 times on days 0 (D0), 2 (D2), and 4 (D4) with PBS, SSP-SAP alone, in combination with FAM, or Blank-SP in combination with FAM.Mice were treated 3 times on days 0 (D0), 2 (D2), and 4 (D4) with PBS, SSP-SAP alone, in combination with FAM, or Blank-SP in combination with FAM.. To inhibit NK1R, mice received 30 nmol of the antagonist FK888 (Tocris, cat #2400), which has been previously used i.n. in guinea pigs .. Mice were treated 3 times on days 0 (D0), 2 (D2), and 4 (D4) with only FAM or FK888 in combination with either PBS, Sar-SP, or FAM.Mice were treated 3 times on days 0 (D0), 2 (D2), and 4 (D4) with only FAM or FK888 in combination with either PBS, Sar-SP, or FAM.



    Similar Products

    fk 888  (Bio-Techne corporation)
    91
    Bio-Techne corporation fk 888
    Fk 888, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/antagonist+fk888/FK+888/custom%402400%4039454987
    Average 91 stars, based on 1 article reviews
    fk 888 - by Bioz Stars, 2026-10
    91/100 stars
    		  Buy from Supplier
    antagonist fk888  (Tocris)
    91
    Tocris antagonist fk888
    (A) Protocol for treatment of WT mice with either 3 i.n. doses every other day of PBS (gray), FAM with blank peptide conjugated to saporin (FAM 3X+Blank-SP, blue), [Sar ,Met(O 2 ) ]–Substance P conjugated to saporin (SSP-SAP 3X, green), or FAM with SSP-SAP (SSP-SAP 3X + FAM 3X, red) analyzed on D5. Data depicted in (C), (E), (G), (H), (K), (L), (O), and (P). (B) Protocol for treatment of WT mice with 3 i.n. doses every other day of either the NK1R inhibitor <t>FK888</t> and PBS (FK888 3X + PBS 3X, gray), vehicle with FAM (Vehicle 3X + FAM 3X, blue), the NK1R inhibitor with Sar-SP (FK888 3X + Sar-SP 3X, green), or FK888 with FAM (FK888 3X + FAM 3X, red). Data depicted in (D), (F), (I), (J), (M), (N), (Q), and (R). (C-D) Sinonasal wash levels of IL-5 (left) and IL-13 (right) in (C) protocol (A), ablate or (D) protocol (B), inhibit. (E-F) Sinonasal wash levels of (E) IL-25 (left) and CysLT (right) for protocol (A, ablate) or (F) for protocol (B, inhibit). (G-J) Total number of respiratory tissue (G,I) Tuft-1 and (H,J) Tuft-2 cells in the (G-H) protocol (A), ablate or (I-J) in protocol (B), inhibit. (K-N) Total number of respiratory tissue (K, M) Ki-67+ basal cells and (L, M) ILC2s in (K-L) protocol (A), ablate or (M-N) protocol (B) inhibit. (O-R) Total number of respiratory tissue (O, Q) CD4+ TH2 cells and (P, R) eosinophils in (O-P) protocol (A), ablate or (Q-R) protocol (B), inhibit. Data are mean ± SEM, representative of 2 experiments (4-5 mice/treatment), one-way ANOVA with Tukey’s post-hoc tests. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001. See also and .
    Antagonist Fk888, supplied by Tocris, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/antagonist+fk888/FK+888/bio_rxiv__2023__07__04__547596-283-9-11
    Average 91 stars, based on 1 article reviews
    antagonist fk888 - by Bioz Stars, 2026-10
    91/100 stars
    		  Buy from Supplier
    selective nk1 receptor antagonist fk888  (Fujisawa Pharmaceutical Co Ltd)
    90
    Fujisawa Pharmaceutical Co Ltd selective nk1 receptor antagonist fk888
    (A) Protocol for treatment of WT mice with either 3 i.n. doses every other day of PBS (gray), FAM with blank peptide conjugated to saporin (FAM 3X+Blank-SP, blue), [Sar ,Met(O 2 ) ]–Substance P conjugated to saporin (SSP-SAP 3X, green), or FAM with SSP-SAP (SSP-SAP 3X + FAM 3X, red) analyzed on D5. Data depicted in (C), (E), (G), (H), (K), (L), (O), and (P). (B) Protocol for treatment of WT mice with 3 i.n. doses every other day of either the NK1R inhibitor <t>FK888</t> and PBS (FK888 3X + PBS 3X, gray), vehicle with FAM (Vehicle 3X + FAM 3X, blue), the NK1R inhibitor with Sar-SP (FK888 3X + Sar-SP 3X, green), or FK888 with FAM (FK888 3X + FAM 3X, red). Data depicted in (D), (F), (I), (J), (M), (N), (Q), and (R). (C-D) Sinonasal wash levels of IL-5 (left) and IL-13 (right) in (C) protocol (A), ablate or (D) protocol (B), inhibit. (E-F) Sinonasal wash levels of (E) IL-25 (left) and CysLT (right) for protocol (A, ablate) or (F) for protocol (B, inhibit). (G-J) Total number of respiratory tissue (G,I) Tuft-1 and (H,J) Tuft-2 cells in the (G-H) protocol (A), ablate or (I-J) in protocol (B), inhibit. (K-N) Total number of respiratory tissue (K, M) Ki-67+ basal cells and (L, M) ILC2s in (K-L) protocol (A), ablate or (M-N) protocol (B) inhibit. (O-R) Total number of respiratory tissue (O, Q) CD4+ TH2 cells and (P, R) eosinophils in (O-P) protocol (A), ablate or (Q-R) protocol (B), inhibit. Data are mean ± SEM, representative of 2 experiments (4-5 mice/treatment), one-way ANOVA with Tukey’s post-hoc tests. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001. See also and .
    Selective Nk1 Receptor Antagonist Fk888, supplied by Fujisawa Pharmaceutical Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/antagonist+fk888/fk888/pm14607108-45-5-14
    Average 90 stars, based on 1 article reviews
    selective nk1 receptor antagonist fk888 - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    nk1 receptor antagonist fk888  (Fujisawa Pharmaceutical Co Ltd)
    90
    Fujisawa Pharmaceutical Co Ltd nk1 receptor antagonist fk888
    (A) Protocol for treatment of WT mice with either 3 i.n. doses every other day of PBS (gray), FAM with blank peptide conjugated to saporin (FAM 3X+Blank-SP, blue), [Sar ,Met(O 2 ) ]–Substance P conjugated to saporin (SSP-SAP 3X, green), or FAM with SSP-SAP (SSP-SAP 3X + FAM 3X, red) analyzed on D5. Data depicted in (C), (E), (G), (H), (K), (L), (O), and (P). (B) Protocol for treatment of WT mice with 3 i.n. doses every other day of either the NK1R inhibitor <t>FK888</t> and PBS (FK888 3X + PBS 3X, gray), vehicle with FAM (Vehicle 3X + FAM 3X, blue), the NK1R inhibitor with Sar-SP (FK888 3X + Sar-SP 3X, green), or FK888 with FAM (FK888 3X + FAM 3X, red). Data depicted in (D), (F), (I), (J), (M), (N), (Q), and (R). (C-D) Sinonasal wash levels of IL-5 (left) and IL-13 (right) in (C) protocol (A), ablate or (D) protocol (B), inhibit. (E-F) Sinonasal wash levels of (E) IL-25 (left) and CysLT (right) for protocol (A, ablate) or (F) for protocol (B, inhibit). (G-J) Total number of respiratory tissue (G,I) Tuft-1 and (H,J) Tuft-2 cells in the (G-H) protocol (A), ablate or (I-J) in protocol (B), inhibit. (K-N) Total number of respiratory tissue (K, M) Ki-67+ basal cells and (L, M) ILC2s in (K-L) protocol (A), ablate or (M-N) protocol (B) inhibit. (O-R) Total number of respiratory tissue (O, Q) CD4+ TH2 cells and (P, R) eosinophils in (O-P) protocol (A), ablate or (Q-R) protocol (B), inhibit. Data are mean ± SEM, representative of 2 experiments (4-5 mice/treatment), one-way ANOVA with Tukey’s post-hoc tests. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001. See also and .
    Nk1 Receptor Antagonist Fk888, supplied by Fujisawa Pharmaceutical Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/antagonist+fk888/fk888/pm10686509-19-1-8
    Average 90 stars, based on 1 article reviews
    nk1 receptor antagonist fk888 - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    nk1 selective antagonist fk888  (Blackwell Science Ltd)
    90
    Blackwell Science Ltd nk1 selective antagonist fk888
    (A) Protocol for treatment of WT mice with either 3 i.n. doses every other day of PBS (gray), FAM with blank peptide conjugated to saporin (FAM 3X+Blank-SP, blue), [Sar ,Met(O 2 ) ]–Substance P conjugated to saporin (SSP-SAP 3X, green), or FAM with SSP-SAP (SSP-SAP 3X + FAM 3X, red) analyzed on D5. Data depicted in (C), (E), (G), (H), (K), (L), (O), and (P). (B) Protocol for treatment of WT mice with 3 i.n. doses every other day of either the NK1R inhibitor <t>FK888</t> and PBS (FK888 3X + PBS 3X, gray), vehicle with FAM (Vehicle 3X + FAM 3X, blue), the NK1R inhibitor with Sar-SP (FK888 3X + Sar-SP 3X, green), or FK888 with FAM (FK888 3X + FAM 3X, red). Data depicted in (D), (F), (I), (J), (M), (N), (Q), and (R). (C-D) Sinonasal wash levels of IL-5 (left) and IL-13 (right) in (C) protocol (A), ablate or (D) protocol (B), inhibit. (E-F) Sinonasal wash levels of (E) IL-25 (left) and CysLT (right) for protocol (A, ablate) or (F) for protocol (B, inhibit). (G-J) Total number of respiratory tissue (G,I) Tuft-1 and (H,J) Tuft-2 cells in the (G-H) protocol (A), ablate or (I-J) in protocol (B), inhibit. (K-N) Total number of respiratory tissue (K, M) Ki-67+ basal cells and (L, M) ILC2s in (K-L) protocol (A), ablate or (M-N) protocol (B) inhibit. (O-R) Total number of respiratory tissue (O, Q) CD4+ TH2 cells and (P, R) eosinophils in (O-P) protocol (A), ablate or (Q-R) protocol (B), inhibit. Data are mean ± SEM, representative of 2 experiments (4-5 mice/treatment), one-way ANOVA with Tukey’s post-hoc tests. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001. See also and .
    Nk1 Selective Antagonist Fk888, supplied by Blackwell Science Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/antagonist+fk888/fk888/pm09720825-56-12-46
    Average 90 stars, based on 1 article reviews
    nk1 selective antagonist fk888 - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    fk888 (nkl antagonist)  (Fujisawa Pharmaceutical Co Ltd)
    90
    Fujisawa Pharmaceutical Co Ltd fk888 (nkl antagonist)
    (A) Protocol for treatment of WT mice with either 3 i.n. doses every other day of PBS (gray), FAM with blank peptide conjugated to saporin (FAM 3X+Blank-SP, blue), [Sar ,Met(O 2 ) ]–Substance P conjugated to saporin (SSP-SAP 3X, green), or FAM with SSP-SAP (SSP-SAP 3X + FAM 3X, red) analyzed on D5. Data depicted in (C), (E), (G), (H), (K), (L), (O), and (P). (B) Protocol for treatment of WT mice with 3 i.n. doses every other day of either the NK1R inhibitor <t>FK888</t> and PBS (FK888 3X + PBS 3X, gray), vehicle with FAM (Vehicle 3X + FAM 3X, blue), the NK1R inhibitor with Sar-SP (FK888 3X + Sar-SP 3X, green), or FK888 with FAM (FK888 3X + FAM 3X, red). Data depicted in (D), (F), (I), (J), (M), (N), (Q), and (R). (C-D) Sinonasal wash levels of IL-5 (left) and IL-13 (right) in (C) protocol (A), ablate or (D) protocol (B), inhibit. (E-F) Sinonasal wash levels of (E) IL-25 (left) and CysLT (right) for protocol (A, ablate) or (F) for protocol (B, inhibit). (G-J) Total number of respiratory tissue (G,I) Tuft-1 and (H,J) Tuft-2 cells in the (G-H) protocol (A), ablate or (I-J) in protocol (B), inhibit. (K-N) Total number of respiratory tissue (K, M) Ki-67+ basal cells and (L, M) ILC2s in (K-L) protocol (A), ablate or (M-N) protocol (B) inhibit. (O-R) Total number of respiratory tissue (O, Q) CD4+ TH2 cells and (P, R) eosinophils in (O-P) protocol (A), ablate or (Q-R) protocol (B), inhibit. Data are mean ± SEM, representative of 2 experiments (4-5 mice/treatment), one-way ANOVA with Tukey’s post-hoc tests. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001. See also and .
    Fk888 (Nkl Antagonist), supplied by Fujisawa Pharmaceutical Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/antagonist+fk888/fk888/pm09302648-27-34-40
    Average 90 stars, based on 1 article reviews
    fk888 (nkl antagonist) - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) Protocol for treatment of WT mice with either 3 i.n. doses every other day of PBS (gray), FAM with blank peptide conjugated to saporin (FAM 3X+Blank-SP, blue), [Sar ,Met(O 2 ) ]–Substance P conjugated to saporin (SSP-SAP 3X, green), or FAM with SSP-SAP (SSP-SAP 3X + FAM 3X, red) analyzed on D5. Data depicted in (C), (E), (G), (H), (K), (L), (O), and (P). (B) Protocol for treatment of WT mice with 3 i.n. doses every other day of either the NK1R inhibitor FK888 and PBS (FK888 3X + PBS 3X, gray), vehicle with FAM (Vehicle 3X + FAM 3X, blue), the NK1R inhibitor with Sar-SP (FK888 3X + Sar-SP 3X, green), or FK888 with FAM (FK888 3X + FAM 3X, red). Data depicted in (D), (F), (I), (J), (M), (N), (Q), and (R). (C-D) Sinonasal wash levels of IL-5 (left) and IL-13 (right) in (C) protocol (A), ablate or (D) protocol (B), inhibit. (E-F) Sinonasal wash levels of (E) IL-25 (left) and CysLT (right) for protocol (A, ablate) or (F) for protocol (B, inhibit). (G-J) Total number of respiratory tissue (G,I) Tuft-1 and (H,J) Tuft-2 cells in the (G-H) protocol (A), ablate or (I-J) in protocol (B), inhibit. (K-N) Total number of respiratory tissue (K, M) Ki-67+ basal cells and (L, M) ILC2s in (K-L) protocol (A), ablate or (M-N) protocol (B) inhibit. (O-R) Total number of respiratory tissue (O, Q) CD4+ TH2 cells and (P, R) eosinophils in (O-P) protocol (A), ablate or (Q-R) protocol (B), inhibit. Data are mean ± SEM, representative of 2 experiments (4-5 mice/treatment), one-way ANOVA with Tukey’s post-hoc tests. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001. See also and .

    Journal: bioRxiv

    Article Title: Neuron-dependent tuft cell expansion initiates sinonasal allergic Type 2 inflammation

    doi: 10.1101/2023.07.04.547596

    Figure Lengend Snippet: (A) Protocol for treatment of WT mice with either 3 i.n. doses every other day of PBS (gray), FAM with blank peptide conjugated to saporin (FAM 3X+Blank-SP, blue), [Sar ,Met(O 2 ) ]–Substance P conjugated to saporin (SSP-SAP 3X, green), or FAM with SSP-SAP (SSP-SAP 3X + FAM 3X, red) analyzed on D5. Data depicted in (C), (E), (G), (H), (K), (L), (O), and (P). (B) Protocol for treatment of WT mice with 3 i.n. doses every other day of either the NK1R inhibitor FK888 and PBS (FK888 3X + PBS 3X, gray), vehicle with FAM (Vehicle 3X + FAM 3X, blue), the NK1R inhibitor with Sar-SP (FK888 3X + Sar-SP 3X, green), or FK888 with FAM (FK888 3X + FAM 3X, red). Data depicted in (D), (F), (I), (J), (M), (N), (Q), and (R). (C-D) Sinonasal wash levels of IL-5 (left) and IL-13 (right) in (C) protocol (A), ablate or (D) protocol (B), inhibit. (E-F) Sinonasal wash levels of (E) IL-25 (left) and CysLT (right) for protocol (A, ablate) or (F) for protocol (B, inhibit). (G-J) Total number of respiratory tissue (G,I) Tuft-1 and (H,J) Tuft-2 cells in the (G-H) protocol (A), ablate or (I-J) in protocol (B), inhibit. (K-N) Total number of respiratory tissue (K, M) Ki-67+ basal cells and (L, M) ILC2s in (K-L) protocol (A), ablate or (M-N) protocol (B) inhibit. (O-R) Total number of respiratory tissue (O, Q) CD4+ TH2 cells and (P, R) eosinophils in (O-P) protocol (A), ablate or (Q-R) protocol (B), inhibit. Data are mean ± SEM, representative of 2 experiments (4-5 mice/treatment), one-way ANOVA with Tukey’s post-hoc tests. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001. See also and .

    Article Snippet: To inhibit NK1R, mice received 30 nmol of the antagonist FK888 (Tocris, cat #2400), which has been previously used i.n. in guinea pigs .

    Techniques:

    (A-K) Outcomes in ablation experiment following PBS (gray), FAM 3X + Blank-SAP (blue), SSP-SAP 3X (green), or SSP-SAP 3X + FAM 3X (red) for: (A) sneezing-like behavior evoked by capsaicin (12µM i.n.), which was counted from 10 min sound and video recording in a treatment-blind manner, numbers and/or percentages of all (B) Tuft-1 cells, (C) NK1R+ Tuft-1 cells, (D) all Tuft-2 cells, (E) NK1R+ Tuft-2 cells, (F) total basal cells, (G) Ki67+ basal cells, (H) NK1R+ basal cells, (I) ILC2, (J) CD4+ TH2 cells, and (K) eosinophils in the respiratory epithelium assessed by flow cytometry. (L-V) Outcomes of inhibitor experiment following PBS (gray), vehicle + FAM 3X (blue), FK888 3X +SAR-SP 3X (green), or FK888 3X + FAM 3X (red) for: (L) sneezing-like behavior evoked by capsaicin, numbers and/or percentages of all (M) Tuft-1 cells, (N) NK1R+ Tuft-1 cells, (O) all Tuft-2 cells, (P) NK1R+ Tuft-2 cells, (Q) total basal cells, (R) Ki67+ basal cells, (S) NK1R+ basal cells, (T) ILC2, (U) CD4+ TH2 cells, and (V) eosinophils in the respiratory epithelium assessed by flow cytometry. Data are mean ± SEM, representative of 2 experiments (4-8 mice/treatment) one-way ANOVA with Tukey’s post-hoc tests. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001.

    Journal: bioRxiv

    Article Title: Neuron-dependent tuft cell expansion initiates sinonasal allergic Type 2 inflammation

    doi: 10.1101/2023.07.04.547596

    Figure Lengend Snippet: (A-K) Outcomes in ablation experiment following PBS (gray), FAM 3X + Blank-SAP (blue), SSP-SAP 3X (green), or SSP-SAP 3X + FAM 3X (red) for: (A) sneezing-like behavior evoked by capsaicin (12µM i.n.), which was counted from 10 min sound and video recording in a treatment-blind manner, numbers and/or percentages of all (B) Tuft-1 cells, (C) NK1R+ Tuft-1 cells, (D) all Tuft-2 cells, (E) NK1R+ Tuft-2 cells, (F) total basal cells, (G) Ki67+ basal cells, (H) NK1R+ basal cells, (I) ILC2, (J) CD4+ TH2 cells, and (K) eosinophils in the respiratory epithelium assessed by flow cytometry. (L-V) Outcomes of inhibitor experiment following PBS (gray), vehicle + FAM 3X (blue), FK888 3X +SAR-SP 3X (green), or FK888 3X + FAM 3X (red) for: (L) sneezing-like behavior evoked by capsaicin, numbers and/or percentages of all (M) Tuft-1 cells, (N) NK1R+ Tuft-1 cells, (O) all Tuft-2 cells, (P) NK1R+ Tuft-2 cells, (Q) total basal cells, (R) Ki67+ basal cells, (S) NK1R+ basal cells, (T) ILC2, (U) CD4+ TH2 cells, and (V) eosinophils in the respiratory epithelium assessed by flow cytometry. Data are mean ± SEM, representative of 2 experiments (4-8 mice/treatment) one-way ANOVA with Tukey’s post-hoc tests. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001.

    Article Snippet: To inhibit NK1R, mice received 30 nmol of the antagonist FK888 (Tocris, cat #2400), which has been previously used i.n. in guinea pigs .

    Techniques: Flow Cytometry